Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE849 + IDE161
- Development stage
- Phase 2
- Lead developer
- IDEAYA Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IDE849 + IDE161 is an investigational, first-in-class combination therapy being developed by IDEAYA Biosciences for the treatment of DLL3-upregulated solid tumors, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma. The combination consists of IDE849 (also known as SHR-4849), a delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC) carrying a topoisomerase-1 (TOP1) inhibitor payload, and IDE161, an oral small-molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG). IDE161 blocks the removal of poly(ADP-ribose) chains generated during the DNA damage response, leading to persistent PARylation and impaired resolution of DNA repair complexes. This mechanism of action is designed to induce the accumulation of TOP1 lesions, thereby enhancing the anti-tumor efficacy and durability of the TOP1-payload ADC, IDE849. The combination is currently being evaluated in a Phase 1 clinical trial.
- Other names
- IDE849 and IDE161IDE-849 and IDE161IDE 849 and IDE161SHR-4849 + IDE161SHR-4849 and IDE161SHR4849 and IDE161SHR 4849 and IDE161
02
Targets
DLL3 (Delta-like ligand 3)PARG (Poly(ADP-ribose) glycohydrolase)
Beyond the preview
Go deeper on IDE849 + IDE161.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE849 + IDE161.